BR112015021503B1 - Composição para uso no tratamento ou prevenção de osteoartrite - Google Patents

Composição para uso no tratamento ou prevenção de osteoartrite Download PDF

Info

Publication number
BR112015021503B1
BR112015021503B1 BR112015021503-3A BR112015021503A BR112015021503B1 BR 112015021503 B1 BR112015021503 B1 BR 112015021503B1 BR 112015021503 A BR112015021503 A BR 112015021503A BR 112015021503 B1 BR112015021503 B1 BR 112015021503B1
Authority
BR
Brazil
Prior art keywords
osteoarthritis
zoledronic acid
pharmaceutically acceptable
halogen
substituted
Prior art date
Application number
BR112015021503-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015021503A2 (en
Inventor
Desai Ketan
Original Assignee
Levolta Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levolta Pharmaceuticals, Inc filed Critical Levolta Pharmaceuticals, Inc
Publication of BR112015021503A2 publication Critical patent/BR112015021503A2/en
Publication of BR112015021503B1 publication Critical patent/BR112015021503B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112015021503-3A 2013-03-08 2014-03-07 Composição para uso no tratamento ou prevenção de osteoartrite BR112015021503B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/791,685 2013-03-08
US13/791,685 US9012432B2 (en) 2013-03-08 2013-03-08 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
PCT/US2014/022169 WO2014138712A1 (en) 2013-03-08 2014-03-07 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Publications (2)

Publication Number Publication Date
BR112015021503A2 BR112015021503A2 (en) 2018-05-15
BR112015021503B1 true BR112015021503B1 (pt) 2022-09-06

Family

ID=51488530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021503-3A BR112015021503B1 (pt) 2013-03-08 2014-03-07 Composição para uso no tratamento ou prevenção de osteoartrite

Country Status (12)

Country Link
US (1) US9012432B2 (https=)
EP (1) EP2964209B1 (https=)
JP (2) JP6839491B2 (https=)
KR (1) KR102253394B1 (https=)
CN (1) CN105324113B (https=)
AU (1) AU2014225373B2 (https=)
BR (1) BR112015021503B1 (https=)
CA (1) CA2941346C (https=)
EA (1) EA032067B1 (https=)
ES (1) ES2904365T3 (https=)
MX (1) MX377447B (https=)
WO (1) WO2014138712A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431020B (zh) 2016-03-09 2022-03-29 凯恩塞恩斯株式会社 用于预防或治疗炎症性疾病的肽及其应用
WO2017155234A1 (ko) 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
KR101897122B1 (ko) 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
JP7127616B2 (ja) 2019-06-04 2022-08-30 横河電機株式会社 情報処理装置、アラーム管理システム、及びアラーム管理方法
WO2021163432A1 (en) * 2020-02-12 2021-08-19 Levolta Pharmaceuticals, Inc. Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3776880D1 (de) 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
WO2001047559A1 (fr) * 1999-12-27 2001-07-05 Teikoku Seiyaku Co., Ltd Pastilles a usage externe
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AU2002305809B2 (en) * 2001-06-08 2007-12-06 Ortho-Mcneil Pharmaceutical, Inc. Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
CA2480814A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20090035315A1 (en) * 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases
EP1890727B1 (en) * 2005-05-25 2012-10-03 CaloSyn Pharma, Inc Method and composition for treating osteoarthritis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
SI2049123T1 (sl) * 2006-08-03 2013-04-30 Horizon Pharma Ag Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida
WO2010071866A2 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
WO2010129542A1 (en) * 2009-05-04 2010-11-11 Jie Zhang Methods of treating pains associated with neuroma, nerve entrapment, and other conditions
US8946199B2 (en) 2010-04-26 2015-02-03 Ketan Desai Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion

Also Published As

Publication number Publication date
KR102253394B1 (ko) 2021-05-20
JP6839491B2 (ja) 2021-03-17
CN105324113A (zh) 2016-02-10
EA032067B1 (ru) 2019-04-30
EP2964209A4 (en) 2016-08-03
MX2015011671A (es) 2016-05-12
CA2941346C (en) 2020-03-10
BR112015021503A2 (en) 2018-05-15
WO2014138712A1 (en) 2014-09-12
US20140256681A1 (en) 2014-09-11
CN105324113B (zh) 2018-07-03
AU2014225373B2 (en) 2018-07-05
CA2941346A1 (en) 2014-09-12
EP2964209B1 (en) 2021-10-27
EA201591638A1 (ru) 2016-02-29
KR20150125001A (ko) 2015-11-06
JP2019104762A (ja) 2019-06-27
MX377447B (es) 2025-03-10
AU2014225373A1 (en) 2015-10-22
US9012432B2 (en) 2015-04-21
EP2964209A1 (en) 2016-01-13
ES2904365T3 (es) 2022-04-04
JP2016510765A (ja) 2016-04-11

Similar Documents

Publication Publication Date Title
US8859530B2 (en) Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
BR112015021503B1 (pt) Composição para uso no tratamento ou prevenção de osteoartrite
KR102615210B1 (ko) 난소암의 치료에 사용되는 티노스타무스틴
RU2717331C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
JP2004528340A (ja) ビスホスホネートの医薬的使用
Biteau et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer
CN104203232A (zh) 用于抗肿瘤试剂施用的方法
Levi et al. Stress impairs the efficacy of immune stimulation by CpG-C: Potential neuroendocrine mediating mechanisms and significance to tumor metastasis and the perioperative period
BR112021007283A2 (pt) método de tratamento de um câncer ou câncer refratário
US9463198B2 (en) Compositions and methods for reducing or preventing metastasis
US11135212B2 (en) Method for treating osteoporosis, osteopenia or low bone mineral density
JP2024546584A (ja) Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ
KR20110128916A (ko) 췌장암의 치료
JP2012524078A (ja) 肝細胞癌の治療法
BR112019026378A2 (pt) métodos de tratamento de tumores cerebrais usando terapia de combinação
WO2021163432A1 (en) Co-administration of prednisolone/methyl prednisolone and zoledronic acid to treat and prevent osteoarthritis
JPWO2019087957A1 (ja) 放射性抗腫瘍剤
RU2426555C2 (ru) Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
IT202100009926A1 (it) Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
US20250177352A1 (en) Combination treatment for cancer
JP2008533161A (ja) ＰＰＡＲ−γアンタゴニストを使用するがんの治療方法
BR112012017773B1 (pt) Composto para uso no tratamento da osteoporose e/ou da osteopenia, produto de combinação, formulação farmacêutica e kit
US20030139430A1 (en) Use of organic compounds
WO2022133102A1 (en) Pi3k inhibitors for protection against glucocorticoid-induced atrophy
BR122025017439A2 (pt) Uso de um composto em combinação com temozolomida para o tratamento de glioma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.